A Stage IA trial in healthy volunteers demonstrated acceptable tolerability and protection, with rapid oral BTK and absorption occupancy that persisted beyond the normalization of plasma concentration
A Stage IA trial in healthy volunteers demonstrated acceptable tolerability and protection, with rapid oral BTK and absorption occupancy that persisted beyond the normalization of plasma concentration. raise the depth and amount of response, without significant toxicity. leads to the human major immune insufficiency disease, X-linked agammaglobulinemia (XLA).10 The B…